@PenrithPanthers centre Stephen Crichton says he wants to stay at the foot of the mountains for his whole career. #NRL
@PenrithPanthers centre Stephen Crichton says he wants to stay at the foot of the mountains for his whole career. #NRL
The bodies of a man and another person have been found in a unit on the Gold Coast.
In a quiet corner of the town of Karlstad, 300 kilometres from Stockholm, a Swedish entrepreneur has built Europe's largest gaming company by market value - although most gamers have never likely heard of it. Working out of an unassuming apartment building, Lars Wingefors' Embracer Group, with a team of fewer than 20, has grown by acquisition. And Embracer, which has bought more than a dozen companies during the coronavirus pandemic alone, is not done yet, Wingefors told Reuters in a recent interview.
A New South Wales rally car driver has died in a tragic crash.
Noocube is a natural nootropic brain booster for enhanced productivity, focus and memory, but do the ingredients have negative side effects or are there real benefits to get from this popular cognitive performance enhancer? NooCube Reviews NooCube Reviews Detroit, MI, April 23, 2021 (GLOBE NEWSWIRE) -- NooCube is a nootropic supplement that helps support and enhance your focus, mental speed, and memory. It contains a synergistic blend of vitamins, minerals, and other essential building materials for a healthy, well-functioning brain. Since it launched, NooCube has helped thousands of people improve their cognition, mental performance, and energy levels. If you’re someone who is suffering from brain aging, frequent mental fog, or just want to improve your cognitive performance, then NooCube could be the right product for you. There are multiple causes for deteriorating memory and cognitive function. Older men and women experience these problems at an increased rate. The neural links in our brains begin to slowly lose their strength as we age. If you have ever walked from one room to another and forgotten why you were there, this could be a sign of depreciating brain function and memory. Brain damage can also cause this issue, and even twenty-year-olds can lose the vigor and strength of mind that they used to have. Supplements have claimed to help people improve their memory and brain power for decades. But the industry has been consistently filled with scams and inefficient formulas. The benefits supposedly associated with these supplements are generally the same across the board. Many products in this niche market claim to function as Limitless pills, offering an extensive list of incredible advantages for users. The truth is that the best supplements in the industry keep their claims moderate and ostensibly backed by scientific evidence and research. NooCube is one of the leading new formulas on the brain supplement market. Enhancing cognitive function, heightening concentration and focus, and improving both memory and learning are the main properties associated with NooCube. The product site nevertheless does make some suspicious claims, especially when it comes to the precise effectiveness of the formula. For example, NooCube’s founders say that over 124,000 people have become smarter after taking NooCube. It’s unlikely that the formula has already had that kind of success, and it’s even less likely that it has made people permanently smarter in such quantities. Additional potential benefits of using this supplement include more “mental energy,” better multitasking, higher concentration levels, improved communication, among other things. Sounds great, right? Our task for this review was to dive face-first into the research to figure out what kind of science and evidence supports (or disputes) the main claims of the NooCube website. The core claim of the NooCube sales pitch can be summarized as follows: it “opens up a new plain of possibilities.” We’ll approach this argument with a skeptical but fair lens during this comprehensive review. What is NooCube & How Does it Work? NooCube is described as a daily nutritional supplement containing a synergistic blend of vitamins, minerals, and herbal extracts. This blend of ingredients supports focus, mental speed, memory, and overall cognition. Taking NooCube provides your brain with the essential building blocks for a healthy brain. Best of all, some of the ingredients in NooCube are said to work within 30 to 45 minutes so you don’t have to wait weeks to feel anything like with many other nootropic compounds. The effects of NooCube can last up 8 to 10 hours as well so you can perform when you need to the most. NooCube can deliver incredible results, which is why it’s trusted by thousands of individuals each day. Here’s how NooCube can deliver such potent effects: NooCube strengthens the brain’s ability to make neural connections: NooCube enables the brain to increase the speed at which in can make connections. It does this by improving acetylcholine levels in the brain. Acetylcholine is one of the main neurotransmitters in the brain responsible for memory, concentration, and learning. Higher acetylcholine levels are associated with better neural functioning and overall cognitive performance. NooCube reduces inflammation and damage in the brain: Inflammation and damage to the brain slows down cognitive performance and weakens your ability to think, focus, & learn. NooCube helps reduce inflammation by flooding the body with powerful anti-inflammatory plant compounds and by stimulating the healing process in the brain. It also provides a layer of protection against new inflammation and damage. NooCube improves blood flow to the brain: NooCube helps widen the blood vessels going to and in the brain. This enhances blood flow to the brain, which ensures your brain receives essential nutrients it needs to function properly. It also helps stimulate the healing process and helps your body eliminate inflammation in the brain. Ingredients in NooCube The NooCube contains seven powerful natural ingredients designed to safely & quickly improve your overall cognitive performance. These ingredients are backed by real, clinical data, which is why NooCube is one of the most popular nootropic compounds on the market. (SPECIAL OFFER) Click Here to Get NooCube with an Exclusive Discount Price OnlineThe seven ingredients found in NooCube include: Alpha GPC: Alpha GPC helps increase acetylcholine levels in the brain. Acetylcholine is a neurotransmitter that helps with communication between brain cells, particularly related to cognitive functions known as learning, concentration, and memory. In addition to cognitive enhancement, Alpha GPC is being studied as a popular treatment for Alzheimer’s disease. Huperzine A: Huperzine a plant that acts as a acetylcholinesterase (AChE) inhibitor. AChE breaks down acetylcholine, which is essential for learning. Preventing this enzyme from breaking down acetylcholine levels can improve mental clarity, learning, and concentration. Like Alpha GPC, huperzine is being studied as a possible treatment for Alzheimer’s disease. Cat’s Claw: Cat’s Claw is a vine that grows in the Amazon rainforest. It has been shown to have serious neuroprotective benefits. It is a rich source of antioxidants that reduce inflammation in the brain by destroying free radicals. Caw’s Claw can also protect the brain from future damage. Bacopa: Bacopa is a plant extract that contains compounds known as bacosides. These bacosides are thought to repair neurons and promote new nerve growth. It also helps protect these neurons, which is why it has drawn significant interest as a potential treatment for dementia and Alzheimer’s. Oat Straw: Oat Straw has been seen as a natural brain booster since the Middle Ages. Researchers believe that it works by increasing alpha-2 waves in the brain – which are highly active during periods of wakefulness. It also helps reduce inflammation and improves blood flow to the brain, which may help you feel more awake and alert. L-Theanine & Tyrosine: Theanine is an amino acid commonly found in black and green tea. It helps relieve stress while stimulating neurotransmitters in the brain, creating a relaxed yet alert feeling. L-Tyrosine plays a key role in the manufacturing of dopamine and noradrenaline, two transmitters that influence focus, mood, and mental alertness. These seven natural ingredients help deliver unparalleled improvements in cognitive functions after just one dose. This is why NooCube is one of the most powerful nootropic supplements available and why it’s used by tens of thousands of adults daily. (HUGE SAVINGS TODAY) Click Here to Get NooCube Supplement For The Lowest Price Right Now Can NooCube Really Work? What separates NooCube from other poorly dosed and ineffective nootropics is that it contains ingredients only backed by science. In fact, every ingredient that was added to NooCube has been clinically proven to support cognitive functioning. For example, a study found that giving Alzheimer’s patients alpha GPC three times daily for 180 days demonstrated “consistent improvements in cognitive function test scores.” The placebo group saw no improvements. In another study, people with dementia given alpha GPC showed a ‘definite symptomatic improvement’ in psychometric tests after taking alpha GPC for 90 days. In 1999, a study found that giving high school students huperzine A improved their learning and memory performance compared to a placebo. Another study found that 58% of Alzheimer’s patients given huperzine showed improved memory. In a 2005 Australian study, people taking a daily 300mg extract of Bacopa monnieri showed a significant improvement in memory tests after 12 weeks than those taking a placebo6. Bacopa was also shown to have a significant effect on memory retention in a similar, placebo controlled study of 76 adults in 20027. A 2015 study gave volunteers either a placebo or 800mg green-oat extract (GOE) each day for six days and assessed their cognitive function with a range of computerized tasks. Those taking GOA were able to complete timed tasks faster and also performed better in memory tasks All of these ingredients are clinically studied, so to answer the original question, “can NooCube really work?” Absolutely. There’s no other nootropic supplement with the clinically backed ingredients that NooCube has. If you’re looking to enhance your cognition – look no further than NooCube. (LOWEST PRICE ONLINE) Get NooCube Directly from the Official Website for the Biggest Discount Benefits of NooCube NooCube is one of the few nootropic compounds that can actually back up its’ claims. So what exactly can NooCube do for you? These are the most common benefits as reported by real users: Improved memory recall & critical thinking: NooCube helps stimulate the neurotransmitters in your brain so that they can make faster connections. As your brain makes faster connections, you’ll be able to think more clearly and have much better memory recall. Better focus & concentration: Acetylcholine levels rise as you take NooCube, which help improve your focus & concentration. You’ll be able to complete tasks much easier and will find you aren’t so distracted by outside stimuli after taking NooCube. Improved mood: NooCube helps release dopamine and serotonin, two brain chemicals known as the “pleasure chemicals.” These two chemicals help make you feel good and will improve your overall mood. Improved energy levels: NooCube improves blood flow to the brain, which ensures your brain has the essential nutrients it needs to keep you feeling energized and healthy. These are just a few of the many benefits of NooCube. While results do vary from person to person, almost everybody feels some – if not all of these benefits to a degree. There are plenty of other benefits to taking NooCube as well but these are the main benefits you should experience if you decide to order NooCube today. NooCube Side Effects & Safety The best thing about NooCube is that not only is it effective – it is safe too. Some of the top neuroscientists in the world came together to formula NooCube with both safety and effectiveness in mind. This is why NooCube does not possess any common side effects or pose any adverse health risks to you when you take it. In fact, there haven’t been any reports of adverse reactions while taking NooCube. Its’ ingredients are overwhelmingly safe and tolerated so well that side effects simply do not occur. The manufacturer also makes sure to note that they routinely test their product for purity, potency, and quality to ensure only the highest quality ingredients are used. They also manufacture the product in a GMP-approved facility to ensure the highest standard manufacturing practices are used to prevent contamination in their product. Overall, NooCube is an incredibly safe product and does not pose any risks to your health. If for whatever reason you still feel uncomfortable about taking this product, then you should consult your doctor before trying it. He or she should be able to tell you whether the ingredients will interfere with a medication or whether you are best suited to avoid NooCube. ALSO READ: Noocube Customer Reviews and User Testimonials: Is It Right for You? Four Reasons to Try NooCube There are hundreds of nootropic compounds currently on the market, but none can compare to the power of NooCube. If you’re still unsure about NooCube, then perhaps these four reasons will help you realize NooCube is the #1 nootropic supplement: NooCube uses clinically studied ingredients: Every single ingredient that was added to the formula in NooCube has been clinically studied and proven to support healthy cognition. Plus, every ingredient is overwhelmingly safe and tolerated extremely well so you don’t need to sacrifice the rest of your health to boost your cognition. It was formulated by top neuroscientists: Some of the top neuroscientists in the world came together to formulate NooCube. Their work discovered the most powerful cognitive enhancers in the world and the right doses to maximize effectiveness without sacrificing safety. Thousands of satisfied customers: Since NooCube was launched, thousands of customers from around the world have felt the raw power of NooCube. They’ve experienced a real change in their memory, thinking, mood, and overall cognition simply by adding NooCube to their daily life. Backed by a 60-day money back guarantee: The makers of NooCube are so confident in their product’s ability to deliver real cognitive enhancement that they back their confidence with a 60-day money back guarantee. If you aren’t happy with their product, request a refund within 60 days – no questions asked. NooCube Pricing NooCube is available for purchase directly from the official website, where you’ll find multiple purchase options: One bottle: $39.99Two bottles: $79.99 + one free bottleThree bottles: $119.99 + three free bottles No matter which package you select, NooCube comes with an exclusive 60 day money back guarantee. Every customer who places an order can try NooCube risk free for 60 days. If for any reason you are not satisfied, are not seeing results, or just don’t think the product is working for you, you can return the product risk-free. Final Thoughts Whether you’re an entrepreneur, student, or just someone looking to enhance your cognition, NooCube can help. It is the ideal nootropic supplement for people of all ages, careers, and lifestyles to boost their cognition. Studies are plentiful on the NooCube product website, and they generally do support some of the more mundane benefits that its creators lay claim to. Alpha GPC, for instance was shown to help Alzheimer’s patients improve their cognitive function after 180 days of thrice-daily use. Huperzine A helped young people improve mental performance when taken consistently. Cat’s Claw, Bacopa, Oat Straw, L-Theanine, and L-Tyrosine are all additional ingredients that make an appearance in the proprietary brain formula. The main limitation to the scientific support on the NooCube website is that we don’t know if the ingredients are used in a quantity high enough to replicate the benefits found in the studies. Nonetheless, our overall appraisal of NooCube is positive. People who use the supplement consistently over extended amounts of time are likely to see substantive improvement to memory and overall cognitive function, according to a few landmark studies. If you feel like your mind is slipping, isn’t what it once was, or you just need to improve your performance, then you need to visit the official website of NooCube and order your package today! Official Website: http://noocube.com/ Contact Details: NooCube Email: firstname.lastname@example.org Phone: +1 (646) 568 9679 About MarketingByKevin.com This product review is published by Marketing By Kevin. Marketing By Kevin reviews are researched and formulated by a group of experienced natural health advocates with years of dedication and determination to finding the highest quality health products and wellness programs available. It should be noted that any purchase derived from this resource is done at your own peril. It is recommended to consult with a qualified professional healthcare practitioner before making an order today if there are any additional questions or concerns. Any order finalized from this release’s links are subject to the entire terms and conditions of the official website’s offer. The researched information above does not take any direct or indirect responsibility for its accuracy. Affiliate Disclosure: The links contained in this product review may result in a small commission to Marketing By Kevin if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products. Disclaimer: Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. Product support: email@example.com Media Contact: firstname.lastname@example.org Attachment NooCube Reviews CONTACT: Kevin Mahoney 708-247-1324 email@example.com
In February 2019, after a steep drop in Wirecard's share price, German authorities launched criminal probes into short-sellers and journalists who had accused the company of fraud, and banned investors from betting against the company. Documents seen by Reuters show for the first time that the only independent information - beyond Wirecard's representations - received by Munich prosecutors who launched the criminal probes was a third-hand account of events from a convicted money launderer, Daniel James Harris. The rationale that led to the decisions of prosecutors and regulators to launch the criminal probes and short-selling ban, and whether they were overzealous in supporting Wirecard, are central issues being investigated by a parliamentary inquiry into the company's collapse in Germany's biggest post-war fraud scandal.
About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. Endometrial cancer is the most common gynecologic cancer in the U.S. and the fourth most common cancer in women in North America.2 In addition, about 90,000 women globally die from endometrial cancer each year.1 There are limited treatment options for women whose disease progresses on or after first-line therapy and this is the first companion diagnostic to identify endometrial cancer patients eligible for anti-PD1 immunotherapy. “We are excited to launch this companion diagnostic test with GSK to help recurrent or advanced endometrial cancer patients with limited treatment options,” said Thomas Schinecker, CEO of Roche Diagnostics. “This test provides clinicians with an effective tool to identify patients best suited for treatment with GSK’s JEMPERLI, providing a new therapeutic option for women with MMR-deficient endometrial cancer whose disease progresses on or following initial chemotherapy treatment.” MMR deficiency is most common in endometrial cancer. This companion diagnostic (CDx) provides clinicians with a standardised testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC). FDA approval of the VENTANA MMR RxDx Panel provides clinicians with access to a fully automated, easy-to-use MMR test to identify patients who are eligible for therapy with JEMPERLI. About the VENTANA MMR RxDx PanelThe VENTANA MMR RxDx Panel is a label expansion of Roche’s current on-market VENTANA MMR IHC Panel. VENTANA MMR RxDx Panel is a qualitative immunohistochemistry test intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) in formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue by light microscopy. The OptiView DAB IHC Detection Kit is used for MLH1, MSH2 and MSH6, and the OptiView DAB IHC Detection Kit with the OptiView Amplification Kit is used for PMS2 on a VENTANA BenchMark ULTRA instrument. DNA mismatch repair (MMR) proteins have been clinically proven to be predictive biomarkers for PD-1 targeted therapy; specifically, a loss of expression of one or more MMR proteins might predict an increased likelihood of response to such therapy.3,4,5 PD-1 inhibitors can be effective in cancers with a high frequency of MMR deficiency and/or microsatellite-instability, high (MSI-H) including endometrial cancer.3,5 MMR is a conserved molecular mechanism that functions to correct the improper base substitutions that spontaneously occur during DNA replication. Defects in the MMR machinery have been attributed to mutations in the MMR proteins. About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.All trademarks used or mentioned in this release are protected by law.References Bray F, Ferlay J, et al, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492 Lortet-Tieulent J, J Ferlay, F Bray, and A Jemal. (2018) International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 110, 354-361. Lee YC, S Lheureux, and AM Oza. (2017) Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 29, 47-58. GSK website, https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/ Kato M, Takano M, Miyamoto M, et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol. 2015:26(1):40-45. Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: firstname.lastname@example.org Dr. Nicolas DunantPhone: +41 61 687 05 17 Patrick BarthPhone: +41 61 688 44 86 Dr. Daniel Grotzky Phone: +41 61 688 31 10 Karsten KleinePhone: +41 61 682 28 31 Nina MählitzPhone: +41 79 327 54 74 Nathalie MeetzPhone: +41 61 687 43 05 Dr. Barbara von SchnurbeinPhone: +41 61 687 89 67 Roche Investor Relations Dr. Karl MahlerPhone: +41 61 68-78503e-mail: email@example.com Jon Kaspar BayardPhone: +41 61 68-83894e-mail: firstname.lastname@example.org Dr. Sabine BorngräberPhone: +41 61 68-88027e-mail: email@example.com Dr. Bruno EschliPhone: +41 61 68-75284e-mail: firstname.lastname@example.org Dr. Birgit MasjostPhone: +41 61 68-84814e-mail: email@example.com Dr. Gerard TobinPhone: +41 61 68-72942e-mail: firstname.lastname@example.org Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: email@example.com Dr. Lisa TuomiPhone: +1 650 467 8737e-mail: firstname.lastname@example.org Attachment 23042021_MR_VENTANA MMR RxDx_en
Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of the Executive Committee as of 1 July 2021. Mrs. Dalbiez (a French national) currently is Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career at Deutsche Bank before working for Capital International, a global investment company. CEO Olivier Rigaud commented: "I am really pleased to welcome Aurélie to the ExCo team as a seasoned HR leader who partners closely with the business to develop talent, drive culture, engagement, continuous improvement, and customer intimacy. Her appointment will also further enhance the diversity of our ExCo." Mrs. Dalbiez brings a multi-cultural background and perspective. She lived in the United States as a child, earned her university degree in International Business in Lyon, France and worked internationally throughout her career, mainly in Switzerland with assignments in Spain, Germany and France. She is fluent in French and English and also speaks German and Spanish. She is married and has three children. With this appointment, the Executive Committee will consist of: Olivier Rigaud (CEO), Eddy van Rhede van der Kloot (CFO), Marco Bootz (President Lactic Acid & Specialties), Aurélie Dalbiez (Chief Human Resources Officer), Jacqueline van Lemmen (Chief Operations Officer), Andy Muller (President Sustainable Food Solutions), Ruud Peerbooms (President Algae Ingredients) and Marcel Wubbolts (Chief Science & Sustainability Officer). Attachment 210423_DalbiezNewCHRO_ENG
GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million Schiphol, the Netherlands – 23 April 2021. GrandVision N.V. publishes its First Quarter 2021 trading update.Due to the exceptional nature of the year 2020, GrandVision will also include in the present press release comparisons versus 2019.Highlights• GrandVision continues to show resilience in the first quarter despite the most recent COVID-19 related government restrictions in Europe and Latam• At constant exchange rates, revenue declined by -0.7% compared with 1Q20 to €899 million from €926 million in 1Q20 (1Q19: €974m)• Comparable revenue declined by -1.5% versus 1Q20 and on a 2019 basis, -10.8% versus 1Q19• Adj. EBITA increased by 98.1% at constant exchange rates to €79 million from €41 million in 1Q20 (1Q19: €107m). Continued cost discipline, structural improvements in certain territories and improved product and price mix contributed to the underlying performance• Adj. EBITA margin at 8.8%, +437bps versus 1Q20 and -219bps versus 1Q19• Approximately 95% of our store network was open at the end of March 2021. Temporary store closures from ongoing government restrictions impacted outlets, mainly in shopping malls. France was the most affected with around 300 stores temporary closed during the period• Net debt at €569 million at the end of March 2021 (FY20: €539m; March 2020: €755m)• European launch of Karün, a 100% sustainable brand using recycled products from Patagonia, Chile• GrandVision joined the United Nations Global Compact initiative• GrandVision to maintain its dividend proposal of €0.35 per share for the fiscal year 2019 at the Annual General Meeting on 23 April 2021 Attachment GrandVision Press Release
Hit BBC police drama is back for an expanded run of episodes
The Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) approved unaudited Telia Lietuva, AB Consolidated Interim Financial Statements, prepared according to International Financial Reporting Standards as adopted by the European Union, for the three months’ period ended 31 March 2021.First quarter of 2021:- Total revenue amounted to EUR 99.7 million, an increase by 8.2 per cent over the revenue of EUR 92.1 million for the first quarter of 2020.- EBITDA was EUR 34.8 million, an increase by 6.1 per cent over EBITDA of EUR 32.8 million a year ago.- Adjusted EBITDA (excluding non-recurring items) amounted to EUR 34 million and was 2.9 per cent higher than adjusted EBITDA of EUR 33 million during the first three months of 2020. - Profit for the period was EUR 13.1 million, up by 4.4 per cent over the profit of EUR 12.5 million a year ago.- Free cash flow amounted to EUR 22.4 million and was 3.8 per cent lower than for the first quarter of 2020 when it amounted to 23.3 million. Management comment:During the first three months of 2021 we continued to operate under second COVID-19 quarantine imposed in Lithuania since November 2020 with our retail outlets partially closed and providing only vital services that could not be offered online. Online sale and remote customer care became extremely important during the pandemic. Closed shops effected sale of mobile devises and cross-border travelling restrictions have a negative impact on revenue from roaming services. Majority of the Company’s employees continue to work from home nevertheless we are preparing for the post-pandemic way of working by introducing the workcation – a possibility to work from any EU country up to one month per year. The Bank of Lithuania forecasts that the country’s GDP during 2021 will increase by 2.9 per cent and during 2022 – by 5.1 per cent, while inflation in 2021 will amount to 1.6 per cent and in 2022 – to 1.9 per cent. The pandemic revealed the importance of connectivity quality and speed. Our continuous investments into upgrade and expansion of both fixed and mobile networks reflects in growing number of customers and the highest average speed of mobile Internet in the country – 93.5 Mbps. In response to increased demand for IT services and solutions we expanded and modernised one of our data centre in Vilnius. EUR 2 million was allocated for this project. Also we have started a strategic project to upgrade our mobile network with Ericsson equipment throughout Lithuania. About 2,000 base stations will be installed over the next three years, making Telia Lietuva network more sustainable, secure and ready for commercial 5G deployment in the future. This will be one of the biggest investment projects ever. In February, we’ve launched eSIM services using the most advance VoLTE technology. We kicked-off with Samsung smartphones and watches, but soon eSIM service will be available with devices of other vendors. By the end of March we already had 80 thousand of households appreciating benefits of unique on the market converged service offer, Telia1. Over the last twelve months:- number of mobile service subscriptions increase by 2.7 per cent up to 1,385,- number of IPTV users grew by 2.8 per cent up to 253 thousand,- number of FTTH Internet customers was up by 1.5 per cent up to 299 thousand. Intake of new customers in combination with the persisting demand for quality connectivity and content as well as IT solutions drives revenue up. Compared with first quarter of 2020 over the year:- revenue from IT services surged by 26.5 per cent,- revenue from TV services grew by 11.6 per cent,- revenue from broadband Internet services increased by 8.7 per cent,- revenue from billed mobile communication services went up by 5.2 per cent. Higher revenue and control of operating expenses resulted in higher earnings in 2021 that a year ago. Also, during the first quarter of 2021 we sold our office building in Kaunas and recorded a EUR 1.2 million gain from this sale. We remain committed to our sustainability agenda. Together with the colleagues from Estonia we are the first in Telia Company Group to reached parity of male and female employed and equal number of male and female managers. Our efforts were recognised during National Responsible Business Awards – Telia Lietuva was named as the Best Employer in 2020 among the large corporations. We are also number one operator in Lithuania according to Sustainable Brand Index rating. As a proof, in March we offered refurbished phones – used but tested smartphones for affordable price. The Company’s Board proposed to the Annual General Meeting of Shareholders that will be held on 27 April 2021 to allocate a record amount of EUR 58.3 million for payment of dividend for the year 2020 (EUR 0.10 dividend per share). ENCL.: - Telia Lietuva, AB Consolidated Interim Financial Statements for the three months’ period ended 31 March 2021.- Presentation of Telia Lietuva AB results for the 3 months of 2021. Darius Džiaugys, Head of Investor Relations, tel. +370 5 236 7878, e-mail: email@example.com Attachments Telia_Lietuva_2021_3_months_Financial_Statements Telia_Lietuva_2021_3_months_results_presentation
AS Tallinna Vesi invites its shareholders, investors, analysts and other stakeholders to join its investor conference webinar, introducing the results for the first quarter of 2021.The webinar is scheduled for 30 April 2021 at 11:00 am (EET) and will be held in English. The webinar will be hosted by Kristi Ojakäär, Chief Financial Officer, and Aleksandr Timofejev, Chief Operations Officer. The questions will be answered by Kristi Ojakäär and Aleksandr Timofejev after the presentation. We encourage participants to send their questions before the webinar takes place, by 9:00 am (EET) on April 30 at the latest, to firstname.lastname@example.org. Questions can also be asked during the webinar. To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/7965867599439776781. The registration will be open until 30 April at 9:00 am (EET). When joining the webinar for the first time, you will be asked to download the plug-in which will take only a few seconds. In case plug-in can't be downloaded, a web browser which enables attending the webinar, opens automatically. Registered participants will receive a reminder e-mail one hour prior to the webinar. The webinar will be recorded and made available online for everyone on the company’s website at www.tallinnavesi.ee and on Nasdaq Baltic YouTube account. Laura KorjusHead of CommunicationsAS Tallinna Vesi(+372) 626 email@example.com
Hitting the road? Keep your belongings safe and organised with these trusty travel companions
INTERIM REPORT for 1 January – 31 March 2021: Verkkokauppa.com’s revenue grew and profitability improved along with strong online sales Verkkokauppa.com Oyj – Interim report 23 April 2021, 8:00 a.m. Verkkokauppa.com arranges two news conferences today. News conference in Finnish is held at 10:00 am Finnish time. Another news conference for analysts and institutional investors is in English is at 11:00 am Finnish time. Details of the events can be found at the end of this release. The complete report is attached to this release and also available at https://investors.verkkokauppa.com/en Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited. 1 January – 31 March 2021 in brief Revenue was 134 million euros (125)Gross profit was 21.7 million euros (19.4) or 16.2% of revenue (15.5%)Operating profit was 5.2 million euros (3.4) or 3.9% of revenue (2.7%)Comparable operating profit was 5.2 million euros (3.8) or 3.9% of revenue (3.0%)Profit for the period was 3.9 million euros (2.4)Earnings per share was 0.09 euros (0.05)Investments were 0.4 million euros (0.3)Operating cash flow was -9.1 million euros (3.7)The Board of Directors decided, according to authorization, to pay the 1st dividend installment of EUR 0.057 per share on 4 May 2021. KEY RATIOS 1-3/20211-3/2020Change, %1-12/2020Eur million Revenue134.0125.37.0%553.6Gross profit21.719.411.9%88.4Gross margin, %16.2%15.5% 16.0%EBITDA6.44.638.4%24.6EBITDA, %4.8%3.7% 4.4%Operating profit5.23.452.2%19.6Operating margin, %3.9%2.7% 3.5%Comparable operating profit5.23.838.5%20.4Comparable operating margin, %3.9%3.0% 3.7%Net profit3.92.457.6%14.6 Investments0.40.362.9%1.4Operating cash flow-9.13.7-348.9%16.9 FINANCIAL GUIDANCE FOR 2021 REMAINS UNCHANGED The company expects the revenue to be between 570–620 million euros (554 million euros) and comparable operating profit to be between 20–26 million euros (20.4 million euros) in 2021. CEO PANU PORKKA’S REVIEW Verkkokauppa.com’s year kicked off strongly. Our revenue grew by 7.0 percent year on year to EUR 134.0 million. The company was able to utilize the transition of retail to online channels well and to respond to consumer demand with a broad product range and versatile delivery options. During the first quarter, Verkkokauppa.com’s online sales, excluding Export, increased by 33 percent year on year, already representing 64 percent of total sales. Growth came from multiple sectors. B2B sales, a strategic focus area for Verkkokauppa.com, increased by 12 percent as expected. Also, the sales of major and small domestic appliances continued to grow. In addition, demand for evolving categories, like sports gear, home & lighting and baby products was good. As for Verkkokauppa.com’s export business, sales decreased due to the pandemic situation and restrictions on traveling. The revenue from our basic operations, i.e. revenue excluding exports, increased in January–March by 16.4 percent year on year. Verkkokauppa.com’s profitability saw strong improvement in the first quarter; gross profit increased by 11.9 percent to EUR 21.7 million, representing 16.2 percent of revenue. Profitability improved especially thanks to the increased share of product categories with higher profit margins in total sales. Our comparable operating profit increased by 38.5 percent year on year to EUR 5.2 million, representing 3.8 percent of revenue. We announced our refined strategy in February. The implementation of the strategy has been started during the spring and we have been concentrating on the further improving the following strategic focus areas: our efficient fulfilment processes and our excellent customer experience. The implementation of our strategy is also bolstered by the biggest investment in our history, which will raise our warehouse throughput and cost efficiency to a new level. This summer we will commence the construction of a fully automated warehouse for small items in connection with our Jätkäsaari logistics center and store. Scheduled to be completed in early 2022, the new warehouse will enable even faster deliveries and better product availability, with considerably more efficient warehouse space utilization. The logistics automation investment is on important step which support us on our journey towards our target of a revenue of one billion euros by the end of 2025. Last year, we took a major leap forward in sustainability by defining and publishing our sustainability focus areas, which include, among others, a smaller environmental impact, our community, a coaching leadership style and valuing differences. This year, we will set measurable and monitored goals for each focus area. FINANCIAL DEVELOPMENT REVENUE AND PROFITABILITY January-March 2021 EUR million1-3/20211-3/2020Change, %FY 2020Revenue134.0125.37.0%553.6 In January-March 2021, Verkkokauppa.com’s revenue grew by 7.0% year on year, totaling 134.0 million euros (125.3). Especially the sales of major domestic appliances, small domestic appliances, office & supplies, gaming & entertainment and sports continued strong. The shift of retail to online channels continued. Verkkokauppa.com’s online sales increased 33 percent year on year, already representing 61 percent of total sales (46%). Visits to the Verkkokauppa.com website increased by 17.6 percent year on year. Sales for corporate customers (B2B) increased 12 percent. As for Verkkokauppa.com’s export business, sales decreased due to the pandemic situation and restrictions on traveling and represented 7 percent of total sales (15 %). The revenue from our basic operations, i.e. revenue excluding exports, increased in January–March by 16.4 percent year on year. Share of sales, % 1-3/20211-3/2020FY 2020 Customer segments Consumer72%68%74% B2B22%22%18% Export6%10%8% Sales channels* On-line64%49%56% Off-line31%32%36% Website visits, million 19.916.987.0 Sales includes orders and deliveries in transit. *) Online and offline sales exclude export sales. The company-financed customer financing proceeds were 1.0 million euros (0.9) including both interest income and fee income. The credit loss allowance was increased by 0.1 million euros (0.0) in the first quarter. Personnel costs increased in January-March by 5.0% to 9.1 million euros (8.6). The increase resulted mainly from IT administration, purchasing, logistics and customer service. During the reporting period, other operating expenses increased slightly to 6.4 million euros (6.3). The increase resulted mainly from higher outsourced logistics service fees and increased credit loss allowance. Operating profit increased 52.2% and was 5.2 million euros (3.4) and 3.9% of revenue (2,7%). Comparable operating profit was 5.2 million euros (3.8) and profit for the period 3.9 million euros (2.4). 1-3/1-3/ 1-12/EUR million20212020Change, %2020Operating profit5.23.452.2%19.6Operating margin, %3.9%2.7% 3.5%- advisory costs related to transfer to official list of Nasdaq Helsinki0.00.3-100.0%0.8Comparable operating profit5.23.838.5%20.4Comparable operating margin, %3.9%3.0% 3.7% Earnings per share were 0.09 euros (0.05) in January-March. FINANCE AND INVESTMENTS Operating cash flow was -9.1 million euros (3.7) in January–March 2021. Operating cash flow was impacted by change in working capital. Drivers for change in working capital were mainly growth in inventories when preparing for high season sales and campaigns, as well as a decline in accounts payable. Ordinary seasonal fluctuations are reflected in cash and cash equivalents, cash flow and accounts payable, which usually reach the highest point at the end of the fourth quarter and the lowest point at the end of the second quarter. Investments totaled 0.4 million euros (0.3) in January–March 2021. During the reporting period the company invested and capitalized 0.0 million euros (0.1) in salary costs and external technology consulting fees related to new IT systems and the development of new ERP features. Verkkokauppa.com has revolving credit facilities totaling 20 million euros, which have not been utilized. Of these credit facilities, 15 million euros are for three years, and 5 million euros for five years as of 1 July 2019. DIVIDEND The Annual General Meeting 2021 resolved to pay dividend 0.056 euros per share and an additional dividend 0.22 euros per share (12,345,341.17 euros in total). The dividend payment date was 7 April 2021. The Board resolved on 23 April 2021 to pay a dividend of 0.057 euros per share (2,549,581.33 euros in total). The dividend payment date is 4 May 2021. Verkkokauppa.com’s Annual General Meeting authorized the Board of Directors to decide in its discretion on the distribution of dividends not exceeding 0.174 euro per share to be paid in three instalments during 2021. REFINED STRATEGY FOR VERKKOKAUPPA.COM On 12 February 2021, the company announced its refined strategy and long-term financial targets (for the period of 2021–2025). With the refined strategy, Verkkokauppa.com targets a revenue of one billion euros and a 5 percent EBIT margin by the end of 2025. At the same time, Verkkokauppa.com will continue its policy of distributing a quarterly growing dividend to shareholders. Verkkokauppa.com’s vision is to remain as a pioneer of ecommerce also in the next decades through continuous innovation and development. SHORT-TERM RISKS AND BUSINESS UNCERTAINTIES Verkkokauppa.com Oyj’s risks and uncertainties reflect the market and general economic trends, for example, demand for consumer electronics, wholesale trade business, the business environment and competition. The company’s business operations are also influenced by risks and uncertainties relating to, for example, business strategy, investments, procurement and logistics, information technology, and other operative aspects of the business. The aforementioned risks and uncertainties may affect the company’s operations, financial position and performance both positively and negatively. Risks and uncertainties have been presented in more detail in the Annual Report. Uncertainty in the development of the economy and the financial markets in Finland, Europe and the world may have a negative impact on the business and growth opportunities of Verkkokauppa.com. The COVID-19 pandemic affects people’s lives and the operation of businesses in Finland and globally alike. The COVID-19 pandemic continues, and its overall impacts on the Company’s business are difficult to assess. BUSINESS OUTLOOK FOR 2021 Verkkokauppa.com Oyj’s business operations are estimated to develop positively in the future. The company believes that it will succeed in further growing its market share in the chosen categories. The strong balance sheet enables the company to continue expanding its operations in accordance with its strategy. The company has benefited from the shifting consumer behavior accelerated by the COVID-19 pandemic, as the sales in the online sales channel have shown strong growth. The company expects this trend to continue the longer the COVID-19 pandemic persists. At the same time, the COVID-19 pandemic continues to have a negative impact on spending on travel and service sectors. This has positively affected the consumer demand for goods, but on the other hand, it has limited the lower-margin wholesale business. The COVID-19 situation may have an impact on the company’s operations and its ability to safely serve customers in the brick-and-mortar stores. The uncertainties concerning the future business outlook remain and relate to macroeconomic developments and the prevailing COVID-19 situation. The pandemic may still cause unforeseen impacts on the overall economic development, consumer demand as well as consumer purchase behavior and B2B sales in the future. Nevertheless, the company believes that it is well positioned and will be a relative winner in the “new normal” business environment of the future. FINANCIAL GUIDANCE FOR 2021 REMAINS UNCHANGED (published on 12 February 2021) The company expects the revenue to be between 570–620 million euros (554 million euros) and comparable operating profit to be between 20–26 million euros (20.4 million euros) in 2021. NEWS CONFERENCES A press conference for analysts, investors and media will be held in Finnish by LiveStream webcast on Friday, 23 April 2021 at 10:00 a.m. (EEST), in which Verkkokauppa.com Oyj’s CEO Panu Porkka will present the developments in the reporting period. A press conference in English will be held by LiveStream webcast on Friday, 23 April 2021 at 11:00 a.m. (EEST). Questions can be sent beforehand or during the presentation via e-mail to firstname.lastname@example.org. Presentation materials for both events are available at https://investors.verkkokauppa.com/en/presentations. For both press conferences, a LiveStream is available at www.verklive.com. COMPANY RELEASES IN 2021 Verkkokauppa.com Oyj will publish its financial reports as follows: Half-year Report January–June 2021, Friday 16 July 2021Interim Report January–September 2021, Friday 22 October 2021 Helsinki, Finland, 23 April 2021 Verkkokauppa.com Oyj Board of Directors More information: Panu Porkka, CEO email@example.com Mikko Forsell, CFO firstname.lastname@example.orgTel. +358 50 434 2516 Marja Mäkinen, Head of Investor Relationsmarja.email@example.comTel. +358 40 671 2999 Distribution: Nasdaq HelsinkiKey mediawww.verkkokauppa.com Verkkokauppa.com – Probably always cheaper Verkkokauppa.com is Finland’s most popular and most visited Finnish online retailer, with the aim to sell to products to its customer at probably always cheaper prices. Depending on the season, the Company markets, sells, and distributes some 60,000–70,000 products in 26 different main product categories through its webstore, retail stores, and network of pick-up points. The Company has four megastores: in Oulu, Pirkkala, Raisio, and Helsinki, in addition to which products can be collected at more than 3,000 pick-up points. Verkkokauppa.com was founded in 1992 and it is headquartered in Jätkäsaari, Helsinki. The Company’s shares are listed on the official list of Nasdaq Helsinki under the ticker symbol VERK. Attachment Verkkokauppa.com Oyj_Interim Report January-March 2021 Published
U.S. President Joe Biden's climate summit will turn to the issue of technology on Friday, featuring remarks from entrepreneurs Bill Gates and Michael Bloomberg, after Thursday's Earth Day kickoff sought to rally world ambition to reduce global warming. Biden called the two-day meeting with dozens of heads-of-state to declare the United States back at the climate leadership table after his predecessor, former President Donald Trump, withdrew from the Paris agreement to cut greenhouse gas emissions. "The world, as a whole, is moving in this direction," Biden's climate envoy John Kerry told reporters.
Passengers on flights into the UK from India must now enter hotel quarantine as the country is officially added to the UK’s coronavirus travel red list. Anyone who is not a UK or Irish resident or a British citizen will be banned from entering the country if they have been in India in the previous 10 days. Boris Johnson’s former aide Dominic Cummings has been blamed for the leaking of the Prime Minister’s text messages.
A teenage phenom on his way to the NBA has died in a tragic car accident in Los Angeles.
Lobbying of government and Bank of England officials was ‘persistent’, inquiry hears
Former prime minister spoke by phone to Bank’s deputy governor
Coles has launched a special Mother's Day-themed Best Buys range featuring an air fryer for the even lower price of $59. See everything on offer here.
Officials insist they did not feel ‘inappropriate pressure’ from ex-PM’s calls to ministers